Please note: In some countries, EXJADE film-coated tablets is available as JADENU® (deferasirox) tablets.
References: 1. Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007;14(3):183-190. 2. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-1995. 3. Shander A, Sweeney JD. Overview of current treatment regimens in iron chelation therapy. US Hematol. 2009;2(1):56-59. 4. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 2008;88(1):7-15. 5. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051-2052. 6. Nolte F, Angelucci E, Breccia M, et al. Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with deferasirox in transfusion dependent patients with myelodysplastic syndrome: emphasis on optimized dosing schedules and new formulations. Leuk Res. 2015;39(10):1028-1033. 7. Porter JB, Evangeli M, El-Beshlawy A. The challenges of adherence and persistence with iron chelation therapy. Int J Hematol. 2011;94(5):453-460. 8. Goldberg SL, Giardina PJ, Chirnomas D, Esposito J, Paley C, Vichinsky E. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013;60(9):1507-1512.
Disclaimer: This is an international website for EXJADE® (deferasirox) film-coated tablets and is intended for Healthcare Professionals outside the United States. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is based on the EU Summary of Product Characteristics, not your country-specific label, and may contain information that is outside the approved indications in the country in which you are located. Always primarily consider information from the label approved in your country.